Skip to main content

Table 1 Patient characteristics

From: Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases

No. Age Gender BSA (m2) MSKCC risk Metastatic sites Prior therapy
1 70 Female 1.298 Intermediate Lung, Lymph nodes None
2 58 Female 1.446 Favorable Abdominal wall, Lung, liver None
3 56 Male 1.929 Intermediate Lung Interferon
4 79 Male 1.710 Favorable Pancreas, Contralateral kidney None
5 62 Male 1.893 Favorable Pleura None
6 64 Male 1.659 Intermediate Lung None
  1. BSA, body surface area; MSKCC, Memorial Sloan-Kettering Cancer Center classification.